The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

The FDA has accepted Moderna’s revised approach seeking full approval for the shot for adults aged between 50 and 64, and accelerated approval for those aged 65 and above, the company said, adding ...

Moderna is a well-known biotech company from its pandemic success. Here's what investors should know about its growth story now.

One week after saying it was refusing to review Moderna’s application for approval of a new flu vaccine, the US Food and Drug ...

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

The brain's ability to carry out everything from forming memories to coordinating movement depends on its cells producing the right proteins at the right time.

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for ...

The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, company and federal officials said ...

After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday, ...

The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is “part of a disturbing pattern” of moving regulatory goalposts, according to Clay Alspach, executive director of the Alliance for mRNA ...

As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with ...